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Abstract
Background: We investigated the effects of glutamine (Gln)-enriched nutritional therapy during chemotherapy on
the nutritional status and immune function of children with acute lymphoblastic leukemia (ALL).
Methods: We enrolled 48 children who were newly diagnosed with ALL in our department during the period
of 2013.1-2014.12. The patients (follow random number table) were randomly divided into the control group
(peptamen) and the treatment group (peptamen + glutamine), 24 cases in each group. The remission induction
regimens were all based on VDLP (D) chemotherapy (VCR (Vincrisstine), DNR (Daunomycin), L-ASP (L-Asparagiase),
Prednisolone and Dexamethasone). The treatment group received Gln-enriched nutritional therapy every day
during the full course of chemotherapy,and the control group is as same as the treatment group except without
glutamine. The indicators of general nutritional status, such as weight, height, and triceps skinfold thickness, and
the indicators of biochemical tests, such as serum albumin, prealbumin, creatinine-height index, retinol binding
protein, and urinary hydroxyproline index, were compared between the two groups at the end of the first,
second, third and the fourth week when the chemotherapy was completed. And in the fourth week, flow
cytometry was applied to detect the levels of T cell subsets and the activities of natural killer (NK) cells in
peripheral blood of the two groups.
Results: 1. after 4 weeks nutritional therapy, there is no significant difference (p > 0.05) between the two groups
of children in weight, height and other indicators. 2. At the end of 2 weeks treatment, the level of prealbumin
(PA) and retinol-binding protein (RBP) is higher in treatment group than that in the control group (P <0.05), at
the end of 3 weeks treatment, the thickness of triceps skinfold is higher (P <0.05) than that in the control group;
3. At the end of 3 and 4 weeks, the concentrations serum ALB, PA, RBP and UHI were higher than in the control
group (P <0.05); 4. There is statistically significant (p < 0.05) between the two groups in edema incidence; 5. At
the end of treatment (4 weeks), the percentages of CD3 +, CD4 +, CD4 +/CD8 +, NK cell are significantly decreased
in the two groups (P <0.05).
Conclusion: Gln-enriched nutritional therapy can effectively improve the systemic nutritional status of children
with leukemia, improve immune function.
Keywords: Childhood acute lymphoblastic leukemia (ALL), Glutamine (Gln), Nutrition therapy, Immune function,
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Acute lymphoblastic leukemia (ALL) is the most common
childhood cancer, and has serious impact on children’s
health. With the rapid development of molecular biology
and optimization of chemotherapy, the current remission
and disease-free survival rates of childhood ALL have
been significantly improved, and the 5-year disease-free
survival rate has reached about 90 % [1]. ALL has become
an excellent example that benefits from modern cancer
treatment. Intensive chemotherapy brings positive ef-
fects, but also significantly increases the incidences of
chemotherapy-related complications and malnutrition,
seriously affecting the quality of life of children [2–4].
Therefore, individualized treatment strategies that aim at
reducing side effects related to chemotherapy and improv-
ing quality of life in children with leukemia have gained
increasing attention [5, 6]. Currently, there are nutrition
guidelines for adult cancer patients in China [7]. Studies
in China and abroad have shown that glutamine (Gln)-
containing nutritional therapy can improve the nutritional
status of adult cancer patients [8, 9]. At present, nutrition
therapy guidelines for children with leukemia are still
missing, and there have been limited numbers of studies
in this field. Clinicians in hematology generally focus on
the improvement of chemotherapy, and the relapse ten-
dency of pediatric patients with ALL. In contrast, evalu-
ation of the overall nutritional status of children with ALL
before and after chemotherapy, and the impact of
nutritional status on immune function have been rarely
investigated. This study aimed to explore the effects of
Gln-enriched nutrition therapy that was applied during
chemotherapy on the nutritional status and immune func-
tion of children with ALL, in order to investigate the
mode of nutrition therapy for childhood leukemia, in-
crease the tolerance of chemotherapy in children, enhance
immunity, improve the quality of life of children, and even
help to improve the long-term prognosis. When newly di-
agnosed with ALL, pediatric patients often have heavy
tumor burden and poor general conditions. In addition,
the remission induction VDLP (D) program has long
treatment course and high intensity. Most children have
varying degrees of edema, protein malnutrition, severe in-
fections, and fungal infections after remission induction
chemotherapy, and the incidence of serious complications
after chemotherapy is high. Therefore, we choose time
points before and after the VDLP (D) remission induction
program in newly diagnosed ALL as the starting points of
our investigations.
Case features
Diagnosis criteria: All patients were referring to MICM
classification in China “2014 Diagnosis and treatment of
childhood acute lymphoblastic leukemia (ALL) (fourth
Revised Draft)” [10], and were diagnosed as childhood
acute lymphoblastic leukemia.
Selection criteria: the 31 new ALL patients in our hos-
pital registered rom 2013.1.1 to 2014.12 31; with medium
risk (MR) and standard risk (LR) age from 1 to 12; no
CNS or testicular leukemia extramedullary infiltration
symptoms; no gender and ethnic limitation; guardians of
all the children voluntarily joined the treatment.
Exclusion criteria: patients with severe malnutrition,
endocrine disease, such as the coexistence of severe mal-
nutrition or diabetes at admission; coexistence of central
nervous system leukemia (CNSL) or testicular leukemia;
relapse children ALL; myeloid leukemia; ALL patient
treated by chemotherapy in other hospital.
Grouping method: using randomized number table to
group randomly;
Follow-up: 2 months follow-up after treatment to ob-
serve if there are any long-term adverse effects;
Emergency measures: when patients show serious in-
fections, if it may relate to chemotherapy, the chemo-
therapy must be stopped and strengthen symptomatic
and supportive treatment; if it may relate to nutritional
therapy, nutritional therapy discontinue. When patients
show diarrhea, vomiting and other symptoms, intraven-
ous or oral electrolyte liquid should be given, and close
monitoring the changes of electrolytes, dehydration and
acid-base balance. When the nutritional therapy or
chemotherapy was stopped for more than 1 week, then
the patient must be excluded.
General information
The 48 cases of newly diagnosed ALL were hospitalized
in our hospital during the period of 2013.1-2014.12.
There were 28 males and 20 females that were aged
14 months-11 years and 4 months (136 months), with a
median age of 5 years and 6 months (66 months). The
patients were randomly divided into two groups: the
treatment group (peptamen + glutamine) and the control
group (small peptiedes). There were no significant differ-
ences in age, sex, and severity of disease between the
two groups, total of 48 children received the whole treat-
ment, no exit and death case. The remission induction
program was VDLP (D) chemotherapy. VDLP (D)
method follows < 2014 Diagnosis and treatment of chil-
dren with acute lymphoblastic leukemia (fourth Revised
Draft) > [10]: vincristin, VCR 1.5 mg/m2,D8,D15,D22,D29,
LR-ALL only D8,D15, daunomycin, DNR 20-30 mg/m
2,
D8,D15,D22,D29, LR-ALL only D8,D15, L-Asparaginase, L-
ASP 5000-10000U/m2,q2d × 6-8 doses or Pegaspargase,
PEG-ASP 2500U/m2, D10,D24, prednisolone, Pred 60
mg/m2, D1-7, dexamethasone, Dex 6-8 mg/m2, D8-29;
All parents of children signed the informed consent
form. The nutrition program was formulated by spe-
cialists in the nutrition department of our hospital
and ensured that the two groups of subjects received
similar amounts of calories.
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Nutritional therapy
According to WHO [11] recommended energy standard,
energy requirements for all participants were calculated,
in which protein 12 % to 14 %, and other nutrient intake
volume refer to the recommended amount of Chinese
Nutrition Society (RNI). According to the physiological
requirements of each individual, nutritionists designed
recipes for the patients in the two groups, and independ-
ent eating, eating habits were monitored and recorded
by the nurse on duty;
Enteral nutrition method:
Control group (independent eating + peptamen):
when patients eat less than 60 % of normal
physiological requirements, peptamen can provide
the supplement for energy requirement (note 1),
either by oral or nasal.
Treatment group (independent eating + peptamen +
glutamine): chemotherapy and glutamine during
the whole treatment (note 2), when the patients
eat less than 60 % of the normal physiological
requirements, peptamen can provide the
supplement for energy requirement (note 1),
either by oral or nasal.
Parenteral nutrition program: Different parenteral
nutrition (PN) was given to those patients who cannot
tolerate enteral nutrition.
Control group: Parenteral nutrition (PN1) was given
(note 3).
Treatment group: Parenteral nutrition (PN2) (PN1 +
glutamine, note 4) was given.
Treatment group:
Note1. receipt of peptamen: Nestle products, short
peptide enteral nutrition formulations, calorie
466 kcal/100 g, protein 13.7 g/100 g, the protein
source is whey protein hydrolyzate from the peptide;
fat: 17.5 g/100 g (soybean oil + 60 % medium-chain
fatty acid + soy lecithin), carbohydrate content:
62.8 g/100 g (maltodextrin and sucrose,
lactose-free).
Note 2. receipt of glutamine: 0.4 g/kg.d, Dissolved in
100 ml of warm water or porridge, Bangshidi
biotechnology companies;
Note 3. receipt of PN1:20 % fat emulsion, amino acid
injection, water-soluble vitamins, fat-soluble vitamins,
Huarui pharmaceutical company;
Note 4. receipt of PN2:PN1 + glutamine (20 % power
peptide, L- alanyl -L- glutamine, 0.4 g/kg.d), Huarui
pharmaceutical company.
Nutrition treatment period is 4 weeks.
Observation indicators
Nutritional indicators
General nutritional indicators: The following general
indicators of nutritional status were measured at the
end of the first, second and third week of chemo-
therapy and at the fourth week after the end of
chemotherapy: weight, height, and triceps skinfold
thickness;
Biochemical indicators: At the above time points,
fasting blood specimens were collected from the two
groups. We measured the levels of serum albumin
(ALB), prealbumin (PA), and retinol binding protein
(RBP). Urine specimens from the same time period
were collected for the detection of urine creatinine and
urinary hydroxyproline proline in order to calculate
the urinary creatinine-height index (CHI) and urinary
hydroxyproline index (UHI). The normal reference
values of serum RBP, PA, ALB were 30 ~ 70 mg/L,
200 ~ 400 mg/L, and 35 ~ 55 g/L, respectively. At the
same time points, 24-h urine was collected, and uri-
nary creatinine levels were determined by Folin colo-
rimetry. We calculated the CHI values [24-h urine
creatinine excretion (mg) of the subject/24-h urinary
creatinine excretion (mg) of healthy control of the
same height]. Colorimetry was applied to determine
the 24-h urinary hydroxyproline excretion to calculate
the UHI [urinary hydroxyproline (μmol/ml) × weight
(kg)/urine creatinine (μmol/ml)].
Immune indicators
T lymphocyte subsets levels were recorded for the
two groups of children before chemotherapy. At the
end of the fourth week, we used immunofluorescence
and flow cytometry (FCM) to detect the levels of T-
cell subsets in peripheral blood and calculate the per-
centage of NK cells.
Edema observation
Edema indexing standard is from “Zhu Fu Tang Practical
Pediatrics” eighth edition [12]:
Mild edema: edema occurs only in the eyelid, the
soft tissue of lower eye frame and, the soft tissues
of tibialis anterior and ankle, after shiatsu, tissue
showed mild depression, which can be quickly
recovered;
Moderate edema: visible edema in all body loose
tissues, after shiatsu, tissues showed deep depression,
recovery slower;
Severe edema: visible edema in all body tissues,
downcast tissues showed shiny tension, even with
liquid exudation; it may also be associated with
effusion in chest, abdomen and sheath.
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Statistical analysis
Statistical analysis was conducted using the SPSS 14.0 soft-
ware. The measurement data were expressed as mean ±
standard deviation (x ± s), intergroup comparison was con-
ducted using the t test. Repeat sequence data using analysis
of variance and chi-square test was used for the compari-
son of rate. P <0.05 was considered statistically significant.
Results
1) Before treatment, there is no significant difference
(P > 0.05) between the two groups in weight, height,
and triceps skinfold thickness;
2) after 4 weeks nutrition therapy, there is no
significant difference (P > 0.05) in height and weight
of the children in the two groups, compared with
that before the treatment;
3) after the 3 weeks treatment, the triceps skinfold
thicknesses in the two groups are higher than those
in the control group (P <0.05) (Table 1).
Before treatment, there is no statistically difference (P> 0.05)
in ALB, PA, RBP, CHI ad UHI for the two groups
1) At the end of first week, there is no statistically
difference (P > 0.05) in ALB, PA, RBP, CHI and UHI
for the two groups;
2) At the end of second week, the level of PA and RBP
in treatment group is higher than that in the control
group (P < 0.05), and there is no statistically
difference in ALB, CHI and UHI;
3) At the end of third and fourth week, the levels of
ALB, PA, RBP and UHI are higher in the treatment
group than that in the control group (P < 0.05), and
there is no statistically difference in CHI for the two
groups (Table 2).
At the end of fourth week, edema incidence is 20.83 % in
the treatment group and 50 % in the control group (X2 =
4.46, P < 0.05), there is no statistically difference. There
are more severe edema cases in the control group than
that in the treatment group (X2 = 0.437,P > 0.05) (Table 3)
1) Before treatment, there is no statistically difference
in the percentage of CD3+, CD4+, CD4+/CD8+ and
NK cells for the two groups (P > 0.05);
2) After 4 weeks chemotherapy, there is statistically
difference in the percentage of CD3+, CD4+, CD4+/
CD8+ and NK cells (P < 0.05) for the control group,
and there is statistically difference in CD3+, CD8+
and NK cells (P < 0.05) for the treatment group;
3) After 4 weeks chemotherapy, there is statistically
difference in CD3+, CD4+, CD4+/CD8+ and NK
cells for the control and treatment groups (P < 0.05)
(Table 4).
Discussions
The complete remission rate and disease-free survival
rate of childhood ALL have been significantly improved.
This improvement can be attributed to accurate MICM
classification and correct assessment of disease severity
of pediatric patients. But it is mainly due to the applica-
tion of L-asparaginase (L-ASP) and other chemotherapy
drugs. L-ASP, as a potent anticancer drug, is widely used
in childhood ALL chemotherapy, and plays a milestone
role in combination chemotherapy [13–15]. The anti-
tumor mechanism of L-ASP has not been elucidated,
but it has been widely accepted that the potential target
for its role is to inhibit protein synthesis [16]. At the
same time that L-ASP exerts the effective anti-tumor
effect, it also produces a series of adverse reactions
such as myelosuppression, hypersensitivity, blood clotting
abnormalities, and gastrointestinal symptoms, making
Table 1 General nutritional indicator of the two groups of ALL Children at the end of the 1st、2nd、3rd and the 4th week (x ± s)
Parameters n Weight (kg) Height (cm) Triceps skinfold thickness (mm)
Treatment group 24
Before treatment 29.02 ± 1.23 116.71 ± 4.26 12.09 ± 1.69
The end of 1st week 28.98 ± 3.00 116.74 ± 4.33 12.12 ± 1.87
The end of 2nd week 27.46 ± 2.53 116.76 ± 4.36 11.45 ± 1.79
The end of 3rd week 29.65 ± 3.24 116.79 ± 4.34 12.62 ± 1.86
The end of 4th week 30.78 ± 3.76 116.80 ± 4.32 13.45 ± 1.73
Control group 24
Before treatment 29.28 ± 2.67 117.24 ± 3.68 12.02 ± 1.09
The end of 1st week 29.21 ± 2.83 117.26 ± 3.99 11.97 ± 1.21
The end of 2nd week 28.57 ± 2.14 117.29 ± 3.95 10.78 ± 1.15
The end of 3rd week 30.02 ± 3.51 117.31 ± 3.86 10.34 ± 1.24a
The end of 4th week 29.53 ± 3.21 117.32 ± 3.82 11.12 ± 1.12
acompare with control group, P < 0.05
Han et al. Nutrition Journal  (2016) 15:65 Page 4 of 8
L-ASP a double-edged sword in the treatment of child-
hood ALL. Children with ALL are in conditions that ca-
tabolism is in the dominant state. Patients have a serious
shortage of calories and protein intake, and have an in-
creased consumption of body protein, while liver infiltra-
tion and liver damage can further affect protein synthesis.
Application of L-ASP-containing chemotherapy further
inhibits protein synthesis, eventually leading to protein
malnutrition, decreased immune function, increased mor-
tality, and seriously affecting the subsequent chemother-
apy. Owens JL [17] suggested that declining nutritional
status of children with leukemia after chemotherapy is a
potential risk factor, and it can reduce immune function,
change drug metabolism, enhance drug toxicity, and pro-
long wound healing. There are currently no uniform
guidelines on nutrition therapy of children with cancer
and no optimal nutrition formula targeting nutrition defi-
ciency in children with leukemia due to chemotherapy. It
is thus beneficial to establish unified diagnostic criteria for
malnutrition and evidence-based nutrition guidelines for
children with acute lymphocytic leukemia for appropriate
nutritional intervention. In 2009, the American Society of
Parenteral and Enteral Nutrition (ASPEN) published clin-
ical nutritional guidelines for cancer patients [18], empha-
sizing that there is no evidence to indicate that nutrition
therapy can promote the growth of tumour cells. It
provides a theoretical basis for us to apply nutrition the-
rapy during the chemotherapy for children with ALL.
Based on our successful experience in nutrition therapy
for adult cancer patients, we used enhanced Gln nutrition
therapy in pediatric ALL patients during chemotherapy,
and observed the effects on the immune function and
nutrition indicators of children.
Gln is the most abundant non-essential amino acid in
the muscle, accounting about 60 % of total free amino
acids in the human body. It has been proven that Gln
has multifaceted roles. For example, Gaurav K et al. [19]
found that Gln could reduce mucosal injury caused by
radiotherapy and chemotherapy in patients with acute
leukemia, as well as gastrointestinal toxicity caused by 5-
FU, reduce the paclitaxel-related myalgia and arthralgia,
prevent paclitaxel neurotoxicity, alleviate the immuno-
compromised state of laboratory animals after MTX
chemotherapy, and stimulate the recovery of neutrophils
in patients with myeloid leukemia after chemotherapy.
Sornsuvit C et al. [20] also confirmed that parenteral
supplementation of glutamine dipeptide could improve
neutrophil function in patients with myeloid leukemia,
reduce chemotherapy-related oral mucositis, and im-
prove the nutritional status of patients.
The specific mechanism of Gln is not fully understood.
Clinical and basic research has been conducted to reveal
Table 2 General nutritional and biochemical indicator measurements of the two groups of ALL patients at the end of the
1st、2nd、3rd and the 4th week (x ± s)
Parameters n ALB (g/L) PA (mg/L) RBP (mg/L) UHI CHI
Treatment group 24
Before treatment 29.45 ± 2.87 106.6 ± 21.58 19.56 ± 1.78 1.38 ± 0.48 75.96 ± 11.69
At the end of 1st week 29.34 ± 3.53 107.5 ± 22.47 19.42 ± 1.94 1.39 ± 0.55 76.21 ± 12.15
At the end of 2nd week 28.69 ± 2.72 113.47 ± 20.56a 21.76 ± 1.89a 1.35 ± 0.51 72.54 ± 13.21
At the end of 3rd week 30.78 ± 2.75a 130.52 ± 22.31a 22.34 ± 2.15a 1.42 ± 0.55a 75.88 ± 14.16
At the end of 4th week 32.57 ± 3.05a 145.71 ± 23.25a 24.59 ± 5.30a 1.49 ± 0.57a 78.22 ± 14.57
Control group 24
Before treatment 29.34 ± 3.67 111.78 ± 21.23 20.57 ± 2.32 1.29 ± 0.51 75.79 ± 12.33
At the end of 1st week 29.11 ± 3.42 110.44 ± 20.54 20.13 ± 2.02 1.28 ± 0.46 75.59 ± 12.08
At the end of 2nd week 28.77 ± 3.09 100.85 ± 19.78 19.78 ± 2.11 1.26 ± 0.41 73.14 ± 12.79
At the end of 3rd week 26.90 ± 3.54 112.62 ± 20.01 20.05 ± 2.52 1.15 ± 0.38 72.21 ± 12.58
At the end of 4th week 27.15 ± 3.29 110.57 ± 21.22 19.52 ± 2.49 1.18 ± 0.36 72.75 ± 12.93
acompared with control group, P < 0.05
Table 3 Edema after 4 weeks treatment
Parameters n Cases of edema Cases of severe edema Percentage of edema (%)
Treatment group 24
5 1 20.83 %a
Control group 24
12 4 50 %
acompared with control group,P < 0.05
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the mechanisms underlying Gln functions. Goto M et al.
[21] revealed in the study of acute myeloid leukemia
(AML) that Gln might play an important role in energy
metabolism in the Krebs cycle through its effects on
redox balancing. Emadi A et al. [22] found that the se-
lective inhibition effects of Gln led to the growth inhib-
ition of myeloid leukemia cells with defects in the IDH
gene. Based on the Warburg effect theory, there have
been trials using chemical metabolic inhibitors to treat
hematological malignancies, including childhood ALL
[23, 24]. The above studies provide a theoretical basis
for the application of Gln in the adjuvant treatment of
leukemia. But there are only limited numbers of reports
using Gln as an immune and nutrition agent and analyz-
ing the effects of Gln on the nutritional status and im-
mune function of children with ALL from the point of
view. Only a couple of studies conducted small-sample
short-course observations [25], and there is still the lack
of large-sample, and multi-center in-depth studies.
Evaluation of nutritional condition indicators in chil-
dren with leukemia after chemotherapy is extremely
complex. The standard parameters used to assess the
nutritional status of children with cancer may vary very
often. For example, edema after steroid treatment can
mask malnutrition (weight gain leading to fluid reten-
tion), thus impairing the accuracy of using weight as an
indicator for nutritional assessment. Serum protein
markers can show bias if used for the evaluation of mal-
nutrition caused by infections and sepsis. Retinol-
binding protein is the most sensitive indicator reflecting
protein nutrients in diet. In the presence of normal renal
function, CHI is a reliable biochemical parameter meas-
uring muscle protein consumption. Creatinine is a creat-
ine metabolite, and its excretion is closely related to
total muscle content, body surface area and weight. Cre-
atinine is not affected by infusion and fluid retention
and is more sensitive than indicators such as nitrogen
balance and serum ALB. Hydroxyproline is a product of
collagen metabolism. Children with malnutrition and
those with reduced protein levels in the body have re-
duced urinary excretion of hydroxyproline. Therefore,
UHI can be used as a reliable biochemical indicator to
determine the protein nutrition status of children. Flow
cytometry was used to detect the indicators for immune
function in children, and detection of CD3+, CD4+
CD8+, and NK cell numbers is the classic means to assess
immune function. These indicators are sensitive, prac-
tical, stable and reproducible, and are suitable for asses-
sing the nutritional status and immune function of
pediatric patients. Therefore, we selected these indica-
tors to assess changes in the nutritional status and im-
mune function of our patients. It was found that after
the first week of chemotherapy, the two groups of chil-
dren did not show significant differences in weight, ALB,
PA, CHI, RNP, and UHI (p > 0.05), after the second week
of chemotherapy, the pediatric patients in the control
group showed varying degrees of reduction in weight
and triceps skinfold thickness and slow decline in ALB,
PA, RNP, CHI, and UHI, and after the third week of
chemotherapy, both groups had increased weight (due
to the effect of glucocorticoids), whereas the control
group showed an increased proportion of children with
varying degrees of edema, and significant decreases in
ALB, PA, RNP, CHI, and UHI, with significant differ-
ences as compared to the treatment group (p <0.05).
Children in the control group had more cases with se-
vere edema, and the ALB, PA, RNP, CHI, and UHI
levels were significantly lower than those of the treat-
ment group, with significant differences between the
two groups (p <0.05). There was no significant differ-
ence in height between the two groups.
NK cells are the main effector cells in immune cells, and
detecting the level of NK cells is important to assess the
disease initiation, evolution and prognosis of outcome. So
the cellular immune function in the two groups was tested
before and after 4 weeks chemotherapy [26, 27]. Glutam-
ine plays an important role in immune regulation, which
is required for secretion, proliferation and function main-
tenance of lymphocyte. As precursors and primary energy
for nucleic acid biosynthetic, glutamine can promote mi-
tosis, differentiation and proliferation of lymphocytes and
macrophages, and increase the generation of TNF cyto-
kine and IL-1 and the mRNA synthesis of phospholipids.
Providing exogenous glutamine can significantly increase
Table 4 the differences of cellular immune function in the two groups before and after treatment
Parameters Control group (n = 24) Treatment group (n = 24)
Before chemotherapy after 4 weeks Before chemotherapy after 4 weeks
CD3+ 69.23 ± 1.15 55.20 ± 2.96a 70.55 ± 3.05a 63.67 ± 1.64b
CD4+ 32.74 ± 2.85 26.30 ± 2.70a 33.94 ± 2.75 33.83 ± 1.56b
CD8+ 28.45 ± 0.98 28.00 ± 0.88 27.79 ± 0.89a 26.50 ± 1.02b
CD4+/CD8+ 1.16 ± 0.58 0.93 ± 0.10a 1.22 ± 0.65 1.28 ± 0.84b
NK cell % 23.95 ± 2.34 16.23 ± 4.15a 25.47 ± 2.01a 19.54 ± 4.06b
acompared with before chemotherapy,P < 0.05
bcompared with control group,P < 0.05
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the total number of lymphocytes and the ratio of CD4+/
CD8+ in T lymphocytes and circulation, and enhance im-
mune function in critically ill patients, [28–30]. In this
study, glutamine was applied to the leukemia patients re-
ceiving chemotherapy, similar results were also observed.
Our research data showed that after 4 weeks chemothe-
rapy, the percentages of CD3 +, CD4 +, CD4 +/CD8 +, and
NK cell in the two groups were significantly decreased and
there were statistically significant differences (P <0.01) as
compared with that before treatment, which indicated that
the cellular immune function in both groups was seriously
damaged, which suggested that strengthened glutamine
therapy can promote the recovery of immune function in
ALL patients.
In this study, we found that Gln-enhanced nutrition
therapy can significantly improve the nutritional status of
children with ALL, and it can also improve the body’s me-
tabolism and nitrogen balance, promote protein synthesis,
and increase the total number of lymphocytes. Regarding
the safety of glutamine application, in a chronic toxicity
test Wong AW et al. [31] found that after given the rats of
Gln at the dose of 3832-4515 mg/kg for 13 weeks, there
were no obvious toxic reactions found.
During the treatment, all pediatric patients did not show
adverse reactions, including allergic reactions, diarrhea,
bloating, vomiting, and constipation, and most patients
showed good tolerance. This therapy is economical, prac-
tical and worthy of promotion in clinical practices.
The essential amino acids, such as glutamine, can be
synthesized in human body. However, at the beginning
of the experiment, the concentrations of glutamine of
the two groups children were not obtained, so the im-
pacts of the amount of glutamine synthesized by human
body on the experiment results cannot be received,
which is deficiency of the experimental design. In the fu-
ture experiments, we will take care of that, and make
our results more robust.
Conclusions
Gln-enriched nutritional therapy can effectively improve
the systemic nutritional status of children with leukemia,
improve immune function.
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